EXTON, Pa., Nov. 3 – LAWFUEL – The Law News Network – — Isolagen, Inc. (Amex: ILE) announced today that it has engaged Skadden, Arps, Slate, Meagher & Flom, LLP
to represent the Company and other of the defendants named in the various
class action suits. The Company does not expect to respond to the suits until
there has been a consolidation of the complaints and lead plaintiff is
selected at which time the Company expects to file a motion to dismiss the
ABOUT ISOLAGEN, INC.
Isolagen specializes in the development and commercialization of
autologous cellular therapies for soft and hard tissue regeneration. The
company’s product candidates are based on its proprietary Isolagen Process.
Based on the accumulated experience of the company through its retrospective
study, clinical trials and treatment of patients in the United Kingdom, the
company believes that the Isolagen Process utilizes the patient’s own cells to
create safe and effective therapies to treat the underlying cause of the
patient’s condition. Autologous cellular therapy is the process whereby a
patient’s own cells are extracted, allowed to multiply and then injected into
the patient. Isolagen’s product candidates are designed to be minimally
invasive and non-surgical.
Forward-looking statements in this release are made pursuant to the safe
harbor provisions of the federal securities laws. Information contained in
forward-looking statements is based on current expectations and is subject to
change, and actual results may differ materially from the forward-looking
statements. Isolagen, Inc. does not undertake to update any such forward-
looking statements or to publicly announce developments or events relating to
the matters described herein.